Biophytis shares are trading lower after the HAS responded to the company's request for Early Access Authorization for patients suffering from severe forms of COVID-19 and found that the company had not provided sufficient data.
Portfolio Pulse from Benzinga Newsdesk
Biophytis shares are trading lower after the French National Authority for Health (HAS) responded to the company's request for Early Access Authorization for patients suffering from severe forms of COVID-19, stating that the company had not provided sufficient data.
September 19, 2023 | 3:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biophytis shares are trading lower due to the HAS's response to the company's request for Early Access Authorization for severe COVID-19 patients, stating insufficient data.
The denial of Early Access Authorization by the HAS due to insufficient data is a significant setback for Biophytis. This could potentially delay the company's plans to provide treatment for severe COVID-19 patients, which is likely to have a negative impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100